Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Boudewijns, Steve ^a,b   Bol, Kalijn F ^a,b   Schreibelt, Gerty ^b   Westdorp, Harm ^a,b   Textor, Johannes C ^b   van Rossum, Michelle M ^a   Scharenborg, Nicole M ^b   de Boer, Annemiek J ^b   van de Rakt, Mandy W M M ^b   Pots, Jeanne M ^b   van Oorschot, Tom G M ^b   Duiveman de Boer, Tjitske ^b   Olde Nordkamp, Michel A ^b   van Meeteren, Wilmy S E C ^a   van der Graaf, Winette T A ^a,c   Bonenkamp, Johannes J ^a   de Wilt, Johannes H W ^a   Aarntzen, Erik H J G ^a,b   Punt, Cornelis J A ^d   Gerritsen, Winald R ^a   Figdor, Carl G ^b   de Vries, I Jolanda M ^a,b   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cell; DTH; immune response; skin infiltrating lymphocytes; stage III melanoma; vaccination

Indexed keywords

CISPLATIN; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; KEYHOLE LIMPET HEMOCYANIN; MONOPHENOL MONOOXYGENASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; EVALUATION AND FOLLOW UP; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; MIDDLE AGED; RECURRENCE FREE SURVIVAL; VACCINATION; YOUNG ADULT;

EID: 84978036309     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1191732     Document Type: Article

References (38)

1. A.C.van Akkooi, M.G.Bouwhuis, A.N.van Geel, R.Hoedemaker, C.Verhoef, D.J.Grunhagen, P.I.Schmitz, A.M.Eggermont, J.H.de Wilt. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol 2007; 33:102-8; PMID:17161577; http://dx.doi.org/10.1016/j.ejso.2006.10.032
2. F.Erdmann, J.Lortet-Tieulent, J.Schuz, H.Zeeb, R.Greinert, E.W.Breitbart, F.Bray. International trends in the incidence of malignant melanoma 1953–2008–are recent generations at higher or lower risk? Int J Cancer 2013; 132:385-400; PMID:22532371; http://dx.doi.org/10.1002/ijc.27616
3. C.M.Balch, J.E.Gershenwald, S.J.Soong, J.F.Thompson, M.B.Atkins, D.R.Byrd, A.C.Buzaid, A.J.Cochran, D.G.Coit, S.Ding et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx.doi.org/10.1200/JCO.2009.23.4799
4. A.M.Eggermont, A.Testori, J.Marsden, P.Hersey, I.Quirt, T.Petrella, H.Gogas, R.M.MacKie, A.Hauschild. Utility of adjuvant systemic therapy in melanoma. Ann Oncol 20 Suppl 6:vi30-4; PMID:19617295; http://dx.doi.org/10.1093/annonc/mdp250
5. K.Wheatley, N.Ives, B.Hancock, M.Gore, A.Eggermont, S.Suciu. Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29:241-52; PMID:12927565; http://dx.doi.org/10.1016/S0305-7372(03)00074-4
6. A.M.Eggermont, V.Chiarion-Sileni, J.J.Grob, R.Dummer, J.D.Wolchok, H.Schmidt, O.Hamid, C.Robert, P.A.Ascierto, J.M.Richards et al. Adjuvant ipilimumab vs. placebo after complete resection of high-risk stage III melanoma (EORTC 18071):a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16:522-30; PMID:25840693; http://dx.doi.org/10.1016/S1470-2045(15)70122-1
7. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
8. K.Palucka, J.Banchereau. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
9. S.Anguille, E.L.Smits, E.Lion, V.F.van Tendeloo, Z.N.Berneman. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
10. I.J.de Vries, M.R.Bernsen, W.J.Lesterhuis, N.M.Scharenborg, S.P.Strijk, M.J.Gerritsen, D.J.Ruiter, C.G.Figdor, C.J.Punt, G.J.Adema. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23:5779-87; PMID:16110035; http://dx.doi.org/10.1200/JCO.2005.06.478
11. C.G.Figdor, I.J.de Vries, W.J.Lesterhuis, C.J.Melief. Dendritic cell immunotherapy:mapping the way. Nature medicine 2004; 10:475-80; PMID:15122249; http://dx.doi.org/10.1038/nm1039
12. E.H.Aarntzen, G.Schreibelt, K.Bol, W.J.Lesterhuis, A.J.Croockewit, J.H.de Wilt, M.M.van Rossum, W.A.Blokx, J.F.Jacobs, T.Duiveman-de Boer et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18:5460-70; PMID:22896657; http://dx.doi.org/10.1158/1078-0432.CCR-11-3368
13. T.F.Gajewski, Y.Meng, C.Blank, I.Brown, A.Kacha, J.Kline, H.Harlin. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006; 213:131-45; PMID:16972901; http://dx.doi.org/10.1111/j.1600-065X.2006.00442.x
14. A.M.Lesokhin, T.M.Hohl, S.Kitano, C.Cortez, D.Hirschhorn-Cymerman, F.Avogadri, G.A.Rizzuto, J.J.Lazarus, E.G.Pamer, A.N.Houghton et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72:876-86; PMID:22174368; http://dx.doi.org/10.1158/0008-5472.CAN-11-1792
15. P.Sharma, K.Wagner, J.D.Wolchok, J.P.Allison. Novel cancer immunotherapy agents with survival benefit:recent successes and next steps. Nat Rev Cancer 2011; 11:805-12; PMID:22020206; http://dx.doi.org/10.1038/nrc3153
16. E.H.Aarntzen, K.Bol, G.Schreibelt, J.F.Jacobs, W.J.Lesterhuis, M.M.van Rossum, G.J.Adema, C.G.Figdor, C.J.Punt, I.J.de Vries. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell based vaccination in metastatic melanoma. Cancer Res 2012; 72:6102-10; PMID:23010076; http://dx.doi.org/10.1158/0008-5472.CAN-12-2479
17. C.L.Vanderlugt, S.D.Miller. Epitope spreading in immune-mediated diseases:implications for immunotherapy. Nat Rev Immunol 2002; 2:85-95; PMID:11910899; http://dx.doi.org/10.1038/nri724
18. A.Berger. Th1 and Th2 responses:what are they? BMJ 2000; 321:424; PMID:10938051; http://dx.doi.org/10.1136/bmj.321.7258.424
19. E.H.Aarntzen, K.Bol, G.Schreibelt, J.F.Jacobs, W.J.Lesterhuis, M.M.Van Rossum, G.J.Adema, C.G.Figdor, C.J.Punt, I.J.De Vries. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 2012; 72:6102-10; PMID:23010076; http://dx.doi.org/10.1158/0008-5472.CAN-12-2479
20. D.S.Chen, I.Mellman. Oncology Meets Immunology:The Cancer-Immunity Cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
21. A.Giobbie-Hurder, R.D.Gelber, M.M.Regan. Challenges of guarantee-time bias. J Clin Oncol 2013; 31:2963-9; PMID:23835712; http://dx.doi.org/10.1200/JCO.2013.49.5283
22. U.Dafni. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 2011; 4:363-71; PMID:21586725; http://dx.doi.org/10.1161/CIRCOUTCOMES.110.957951
23. K.F.Bol, E.H.J.G.Aarntzen, F.E.M.in 't Hout, G.Schreibelt, J.H.A.Creemers, W.J.Lesterhuis, W.R.Gerritsen, D.J.Grunhagen, C.Verhoef, C.J.A.Punt et al. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology 2016; 5:e1057673; PMID:26942068; http://dx.doi.org/10.1080/2162402X.2015.1057673
24. S.L.Topalian, M.I.Gonzales, M.Parkhurst, Y.F.Li, S.Southwood, A.Sette, S.A.Rosenberg, P.F.Robbins. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996; 183:1965-71; PMID:8642306; http://dx.doi.org/10.1084/jem.183.5.1965
25. A.B.Bakker, S.H.van der Burg, R.J.Huijbens, J.W.Drijfhout, C.J.Melief, G.J.Adema, C.G.Figdor. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int J Cancer 1997; 70:302-9; PMID:9033632; http://dx.doi.org/10.1002/(SICI)1097-0215(19970127)70:3%3c302::AID-IJC10%3e3.0.CO;2-H
26. T.N.Schumacher, R.D.Schreiber. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
27. B.M.Carreno, V.Magrini, M.Becker-Hapak, S.Kaabinejadian, J.Hundal, A.A.Petti, A.Ly, W.R.Lie, W.H.Hildebrand, E.R.Mardis et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348:803-8; PMID:25837513; http://dx.doi.org/10.1126/science.aaa3828
28. L.Delamarre, I.Mellman, M.Yadav. Cancer immunotherapy. Neo approaches to cancer vaccines. Science 2015; 348:760-1; PMID:25977539; http://dx.doi.org/10.1126/science.aab3465
29. W.J.Lesterhuis, G.Schreibelt, N.M.Scharenborg, H.M.Brouwer, M.J.Gerritsen, S.Croockewit, P.G.Coulie, R.Torensma, G.J.Adema, C.G.Figdor et al. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 2011; 60:249-60; PMID:21069321; http://dx.doi.org/10.1007/s00262-010-0942-x
30. W.J.Lesterhuis, I.J.de Vries, G.Schreibelt, A.J.Lambeck, E.H.Aarntzen, J.F.Jacobs, N.M.Scharenborg, M.W.van de Rakt, A.J.de Boer, S.Croockewit et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011; 17:5725-35; PMID:21771874; http://dx.doi.org/10.1158/1078-0432.CCR-11-1261
31. E.H.Aarntzen, I.J.De Vries, W.J.Lesterhuis, D.Schuurhuis, J.F.Jacobs, K.Bol, G.Schreibelt, R.Mus, J.H.De Wilt, J.B.Haanen et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127
32. K.F.Bol, C.G.Figdor, E.H.Aarntzen, M.E.Welzen, M.M.van Rossum, W.A.Blokx, M.W.van de Rakt, N.M.Scharenborg, A.J.de Boer, J.M.Pots et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology 2015; 4:e1019197; PMID:26405571; http://dx.doi.org/10.1080/2162402X.2015.1019197
33. T.G.Berger, B.Feuerstein, E.Strasser, U.Hirsch, D.Schreiner, G.Schuler, B.Schuler-Thurner. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 2002; 268:131-40; PMID:12215381; http://dx.doi.org/10.1016/S0022-1759(02)00189-8
34. A.Reddy, M.Sapp, M.Feldman, M.Subklewe, N.Bhardwaj. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 1997; 90:3640-6; PMID:9345048
35. I.J.de Vries, G.J.Adema, C.J.Punt, C.G.Figdor. Phenotypical and functional characterization of clinical-grade dendritic cells. Methods Mol Med 2005; 109:113-26; PMID:15585917; http://dx.doi.org/10.1385/1-59259-862-5:113
36. K.F.Bol, E.H.Aarntzen, J.M.Pots, M.A.Olde Nordkamp, M.W.van de Rakt, N.M.Scharenborg, A.J.de Boer, T.G.van Oorschot, S.A.Croockewit, W.A.Blokx et al. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunol Immunother 2016; 65:327-39; PMID:26861670; http://dx.doi.org/10.1007/s00262-016-1796-7
37. D.H.Schuurhuis, P.Verdijk, G.Schreibelt, E.H.Aarntzen, N.Scharenborg, A.de Boer, M.W.van de Rakt, M.Kerkhoff, M.J.Gerritsen, F.Eijckeler et al. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 2009; 69:2927-34; PMID:19318559; http://dx.doi.org/10.1158/0008-5472.CAN-08-3920
38. E.H.Aarntzen, I.J.de Vries, J.H.Goertz, M.Beldhuis-Valkis, H.M.Brouwers, M.W.van de Rakt, R.G.van der Molen, C.J.Punt, G.J.Adema, P.J.Tacken et al. Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunol Immunother 2012; 61:2003-11; PMID:22527252; http://dx.doi.org/10.1007/s00262-012-1263-z